Ankylosing spondylitis is an inflammation (chronic inflammatory arthritis) that mostly affects the spine. It generally causes stiffness and pain in the back. Over time, movement of the back gradually becomes limited as the bones of the spine become fused. This fusion is called ankylosing. Ankylosing spondylitis can also involve other joints such as the hips, shoulders and sometimes knees. Over time, it can affect the joints between the ribs and spine, restricting the movement of the chest and causing a difficulty in breathing deeply. Symptoms of ankylosing spondylitis include frequent pain and stiffness in buttocks and the lower back, which comes on progressively after a few weeks or months. At first, discomfort may be felt only on one side, or alternate sides. The pain is usually diffuse and dull, rather than localized. Other symptoms in the early stages include loss of appetite, mild fever, and general discomfort. Currently, there is no cure for AS, but there are treatments and drugs available to manage pain and reduce symptoms.
Market Dynamics
The increasing launches of new drugs for ankylosing spondylitis are expected to drive the market growth during the forecast period. For instance, in November 2021, Pfizer’s XELJANZ (tofacitinib) received marketing authorization by the European Commission, in the European Union for the treatment of active ankylosing spondylitis. It received approval for the administration of 5 mg XELJANZ (tofacitinib) twice daily for the treatment of adults with active ankylosing spondylitis (AS) who have not responded adequately to conventional therapy. The approval of XELJANZ for ankylosing spondylitis was based on the data obtained from a Phase 3, multicenter, randomized, double-blind, placebo-controlled study that evaluated the safety and efficacy of XELJANZ (tofacitinib) 5 mg twice daily versus placebo in 269 adult patients with active ankylosing spondylitis.
Key features of the study:
- This report provides an in-depth analysis of the global ankylosing spondylitis market, provides market size (US$ Mn), and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global ankylosing spondylitis market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Amgen Inc., AbbVie Inc., Pfizer Inc., Novartis AG, Bristol-Myers Squibb Company, CELGENE CORPORATION, Eli Lilly and Company, Cipla Inc., Emcure Pharmaceuticals, Torrent Pharmaceuticals Ltd., UCB S.A., Suzhou Zelgen Biopharmaceuticals Co., Ltd., HENGRUI USA, and Johnson & Johnson Services, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global ankylosing spondylitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ankylosing spondylitis market
Detailed Segmentation:
- Global Ankylosing Spondylitis Market, By Drug Type:
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Disease-modifying Anti-rheumatic Drugs (DMARDs)
- TNF Inhibitors
- Corticosteroids
- Others
- Global Ankylosing Spondylitis Market, By Route of Administration:
- Global Ankylosing Spondylitis Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Ankylosing Spondylitis Market, By Region:
- North America
- Drug Type
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Disease-modifying Anti-rheumatic Drugs (DMARDs)
- TNF Inhibitors
- Corticosteroids
- Others
- Route of Administration
- Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Latin America
- Drug Type
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Disease-modifying Anti-rheumatic Drugs (DMARDs)
- TNF Inhibitors
- Corticosteroids
- Others
- Route of Administration
- Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Drug Type
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Disease-modifying Anti-rheumatic Drugs (DMARDs)
- TNF Inhibitors
- Corticosteroids
- Others
- Route of Administration
- Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Drug Type
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Disease-modifying Anti-rheumatic Drugs (DMARDs)
- TNF Inhibitors
- Corticosteroids
- Others
- Route of Administration
- Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Drug Type
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Disease-modifying Anti-rheumatic Drugs (DMARDs)
- TNF Inhibitors
- Corticosteroids
- Others
- Route of Administration
- Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- Drug Type
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Disease-modifying Anti-rheumatic Drugs (DMARDs)
- TNF Inhibitors
- Corticosteroids
- Others
- Route of Administration
- Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region/Country
- South Africa
- Central Africa
- North Africa
- Company Profiles
-
- Amgen Inc.
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AbbVie Inc.
- Pfizer Inc.
- Novartis AG
- Bristol-Myers Squibb Company
- CELGENE CORPORATION
- Eli Lilly and Company
- Cipla Inc.
- Emcure Pharmaceuticals
- Torrent Pharmaceuticals Ltd.
- UCB S.A.
- Suzhou Zelgen Biopharmaceuticals Co., Ltd.
- HENGRUI USA
- Johnson & Johnson Services, Inc.
“*” marked represents similar segmentation in other categories in the respective section.
